NCT03906331 2025-01-17Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationEli Lilly and CompanyApproved for marketing
NCT01267461 2012-08-10Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor CellsMeir Medical CenterAvailable